Recursion Pharmaceuticals (RXRX) Gross Profit (2021 - 2026)

Recursion Pharmaceuticals' Gross Profit history runs 6 years deep, the most recent figure standing at -$6.0 million for Q1 2026.

• Quarterly Gross Profit rose 15.05% year-over-year to -$6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 million (up 23.3% YoY) and the FY2025 annual result came in at $3.7 million, down 72.59% from the prior year.
• Gross Profit was -$6.0 million for Q1 2026 at Recursion Pharmaceuticals, down from $21.3 million in the prior quarter.
• Across five years, Gross Profit topped out at $21.3 million in Q4 2025 and bottomed at -$9.5 million in Q3 2025.
• A 5-year average of $286294.1 and a median of -$344000.0 in 2023 frame the typical range for Gross Profit.
• Peak annual rise in Gross Profit reached 4170.64% in 2024, while the deepest fall reached 916.63% in 2024.
• Recursion Pharmaceuticals' Gross Profit stood at $2.8 million in 2022, then slumped by 64.39% to $1.0 million in 2023, then sank by 916.63% to -$8.2 million in 2024, then soared by 357.8% to $21.3 million in 2025, then tumbled by 128.3% to -$6.0 million in 2026.
• Business Quant data shows RXRX's Gross Profit at -$6.0 million in Q1 2026, $21.3 million in Q4 2025, and -$9.5 million in Q3 2025.